The European Society of Cardiology Press Office asked Professor John Martin, ESC Spokesperson for political issues, to comment.
Says Professor Martin,"the action of most modern therapeutics for cardiovascular diseases entails the interaction between a defined molecular species and a receptor or enzyme. As long as appropriate equivalence studies have been performed under the guidance of regulatory authorities, there should be no reason why the manufacture or presentation of a molecule should effect its action. Cheap drugs will help the delivery of health care in Europe."
Says Professor Martin,"the action of most modern therapeutics for cardiovascular diseases entails the interaction between a defined molecular species and a receptor or enzyme. As long as appropriate equivalence studies have been performed under the guidance of regulatory authorities, there should be no reason why the manufacture or presentation of a molecule should effect its action. Cheap drugs will help the delivery of health care in Europe."
Our mission: To reduce the burden of cardiovascular disease.